J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.BO)
INR 1941.8
(4.63%)
INR 1941.8
(4.63%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 8.41 Billion INR | -42.57% |
| 2022 | 13.99 Billion INR | 26.04% |
| 2021 | 11.1 Billion INR | 32.6% |
| 2020 | 8.37 Billion INR | 8.7% |
| 2019 | 7.7 Billion INR | 5.53% |
| 2018 | 7.3 Billion INR | 10.36% |
| 2017 | 6.61 Billion INR | 15.28% |
| 2016 | 5.73 Billion INR | 14.93% |
| 2015 | 4.99 Billion INR | 9.23% |
| 2014 | 4.57 Billion INR | 10.12% |
| 2013 | 4.15 Billion INR | 17.73% |
| 2012 | 3.52 Billion INR | 10.06% |
| 2011 | 3.2 Billion INR | -20.23% |
| 2010 | 4.01 Billion INR | 16.17% |
| 2009 | 3.45 Billion INR | -48.71% |
| 2008 | 6.74 Billion INR | 32.11% |
| 2007 | 5.1 Billion INR | 12.12% |
| 2006 | 4.55 Billion INR | 17.1% |
| 2005 | 3.88 Billion INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.17 Billion INR | 3.2% |
| 2023 Q2 | 3.72 Billion INR | -3.45% |
| 2023 FY | 8.03 Billion INR | -42.57% |
| 2023 Q4 | 2.1 Billion INR | -44.83% |
| 2023 Q3 | 3.81 Billion INR | 2.58% |
| 2023 Q1 | 3.85 Billion INR | 8.4% |
| 2022 Q4 | 3.55 Billion INR | 2.39% |
| 2022 Q1 | 3.45 Billion INR | 21.3% |
| 2022 FY | 13.99 Billion INR | 26.04% |
| 2022 Q2 | 3.51 Billion INR | 1.76% |
| 2022 Q3 | 3.47 Billion INR | -1.17% |
| 2021 Q1 | 2.43 Billion INR | 36.66% |
| 2021 Q4 | 2.84 Billion INR | 0.43% |
| 2021 FY | 11.1 Billion INR | 32.6% |
| 2021 Q3 | 2.83 Billion INR | 3.29% |
| 2021 Q2 | 2.74 Billion INR | 12.67% |
| 2020 Q1 | 1.97 Billion INR | 23.67% |
| 2020 FY | 8.37 Billion INR | 8.7% |
| 2020 Q4 | 1.78 Billion INR | -14.18% |
| 2020 Q2 | 2.17 Billion INR | 9.69% |
| 2020 Q3 | 2.07 Billion INR | -4.31% |
| 2019 Q3 | 2.05 Billion INR | -0.19% |
| 2019 Q4 | 1.6 Billion INR | -22.11% |
| 2019 Q2 | 2.05 Billion INR | 3.34% |
| 2019 Q1 | 1.99 Billion INR | 47.51% |
| 2019 FY | 7.7 Billion INR | 5.53% |
| 2018 Q1 | 1.94 Billion INR | 0.0% |
| 2018 Q3 | 1.92 Billion INR | -7.99% |
| 2018 FY | 7.3 Billion INR | 10.36% |
| 2018 Q4 | 1.35 Billion INR | -29.79% |
| 2018 Q2 | 2.09 Billion INR | 7.63% |
| 2017 Q1 | 1.55 Billion INR | 6.94% |
| 2017 FY | 6.61 Billion INR | 15.28% |
| 2016 FY | 5.73 Billion INR | 14.93% |
| 2016 Q4 | 1.45 Billion INR | 0.0% |
| 2015 Q4 | 1.25 Billion INR | 0.0% |
| 2015 FY | 4.99 Billion INR | 9.23% |
| 2014 FY | 4.57 Billion INR | 10.12% |
| 2013 Q1 | 976.72 Million INR | 0.0% |
| 2013 FY | 4.15 Billion INR | 17.73% |
| 2012 FY | 3.52 Billion INR | 10.06% |
| 2012 Q1 | 830.78 Million INR | 0.0% |
| 2011 FY | 3.2 Billion INR | -20.23% |
| 2010 FY | 4.01 Billion INR | 16.17% |
| 2009 FY | 3.45 Billion INR | -48.71% |
| 2008 FY | 6.74 Billion INR | 32.11% |
| 2007 FY | 5.1 Billion INR | 12.12% |
| 2006 FY | 4.55 Billion INR | 17.1% |
| 2005 FY | 3.88 Billion INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Ajanta Pharma Limited | 30.46 Billion INR | 72.369% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -665.894% |
| Sigachi Industries Limited | 579.88 Million INR | -1351.503% |
| Bal Pharma Limited | 389.89 Million INR | -2058.834% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -296.25% |
| Medico Remedies Limited | 161.84 Million INR | -5100.736% |
| Lasa Supergenerics Limited | 291.17 Million INR | -2790.739% |
| Venus Remedies Limited | 1.91 Billion INR | -339.24% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | -173.566% |
| Alpa Laboratories Limited | 156.14 Million INR | -5290.484% |
| Nectar Lifesciences Limited | 625.55 Million INR | -1245.549% |
| Shilpa Medicare Limited | 2.18 Billion INR | -286.0% |
| Aarti Drugs Limited | 1.16 Billion INR | -620.962% |
| Lupin Limited | 95.67 Billion INR | 91.202% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 78.547% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 80.504% |
| Windlas Biotech Limited | 1 Billion INR | -736.264% |
| Suven Life Sciences Limited | 109.75 Million INR | -7569.32% |
| Eris Lifesciences Limited | 4.94 Billion INR | -70.285% |
| Valiant Laboratories Limited | 36.28 Million INR | -23094.574% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | -83.791% |
| Ipca Laboratories Limited | 13.91 Billion INR | 39.51% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -493.077% |
| Achyut Healthcare Limited | 1.6 Million INR | -523024.86% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 94.541% |
| Bajaj HealthCare Limited | 985.34 Million INR | -754.227% |
| RPG Life Sciences Limited | 1.63 Billion INR | -414.649% |
| Mankind Pharma Limited | 23.15 Billion INR | 63.645% |
| Laurus Labs Limited | 3.01 Billion INR | -179.563% |
| Piramal Pharma Limited | 19.91 Billion INR | 57.733% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -793.154% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 60.708% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 46.961% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 87.542% |
| Unichem Laboratories Limited | 6.72 Billion INR | -25.145% |
| Sequent Scientific Limited | 2.9 Billion INR | -190.063% |
| Novartis India Limited | 470.1 Million INR | -1690.487% |
| Wanbury Limited | 1.16 Billion INR | -625.031% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -500.025% |
| Wockhardt Limited | 6.4 Billion INR | -31.517% |
| Themis Medicare Limited | 782.85 Million INR | -975.177% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -988.307% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 41.766% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 27.693% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 91.221% |
| Divi's Laboratories Limited | 14.17 Billion INR | 40.599% |
| NATCO Pharma Limited | 10.05 Billion INR | 16.315% |
| Gufic Biosciences Limited | 1.07 Billion INR | -681.014% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -666.025% |
| Ind-Swift Limited | 946.56 Million INR | -789.222% |
| Procter & Gamble Health Limited | 2.99 Billion INR | -181.0% |
| FDC Limited | 5.34 Billion INR | -57.372% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -18136.153% |
| Granules India Limited | 7.18 Billion INR | -17.191% |
| Medicamen Biotech Limited | 335.16 Million INR | -2411.309% |
| Alkem Laboratories Limited | 32.83 Billion INR | 74.366% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | -223.684% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -51826.189% |
| Brooks Laboratories Limited | 51.18 Million INR | -16346.032% |
| Megasoft Limited | 49.52 Million INR | -16894.587% |
| ZIM Laboratories Limited | 1.01 Billion INR | -730.859% |
| Strides Pharma Science Limited | 9.16 Billion INR | 8.134% |
| Neuland Laboratories Limited | 2.92 Billion INR | -187.297% |
| Morepen Laboratories Limited | 1.98 Billion INR | -323.511% |
| Hikal Limited | 2.48 Billion INR | -238.533% |
| Indoco Remedies Limited | 4.74 Billion INR | -77.247% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | -173.78% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -1940.865% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -1144.859% |
| Hester Biosciences Limited | 908.84 Million INR | -826.134% |